Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)

By sjmartinez • June 27, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F; ENHANCE investigators. Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials). Am J Respir Crit Care Med. 2023 Jun 26. doi: 10.1164/rccm.202306-0944OC. Epub ahead of print. PMID: 37364283.

Tags: COPD, ensifentrine, nebulized, PDE3 and PDE4 inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Feasibility of cognitive testing and ecological momentary assessments using smartphones in middle aged and older adults with insomnia

Ghadimi S, Ereso J, Kaula AJ, Taptiklis N, Cormack F, Alessi C, Martin JL, Dzierzewski JM, Naeim A, Kremen S, Te T, Fung CH. Feasibility[...]

Unflavored electronic cigarette exposure induces alterations in airway ciliary structure and function

Durra A, Cherry C, Luo C, Hou E, Frauenpreis A, Purkayastha A, Passamano I, Makanani S, Castillo K, Lund A, Choi W, Sen C, Chandran[...]

Heterogeneity in internal medicine chief residency selection processes and role preparation: an opportunity for improvement

Jones BLH, López L, Garg M. Heterogeneity in internal medicine chief residency selection processes and role preparation: an opportunity for improvement. BMC Med Educ. 2025[...]